J&J submits TMC278 NDA

Johnson & Johnson (NYSE:JNJ) submitted an NDA to FDA for rilpivirine ( TMC278) for use with other antiretrovirals in treatment-naive patients with HIV-1. TMC278 is a diarylpyrimidine non-nucleoside re...